July 23, 2020

Theratechnologies Reports That Tesamorelin Improves Liver Health

Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat

 Positive impact of tesamorelin on oxidative phosphorylation, inflammation, tissue repair and cell division

 Montreal, Canada – July 23, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce new data that further support the potential role of tesamorelin in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH).